|
 Inovio will get $27.5 million upfront and potential future payments
of up to $700 million, depending on the success of its INO-3112
immunotherapy, which targets cancers caused by human papillomavirus
(HPV) types 16 and 18.
AstraZeneca said on Monday its MedImmune biotech unit would study
INO-3112 in combination with other immunotherapy drugs.
INO-3112, which is in Phase I/II clinical trials for cervical and
head and neck cancers, works by generating killer T-cell responses
that are able to destroy HPV 16- and 18-driven tumors. The two HPV
types are responsible for more than 70 percent of cervical cancer.
The deal follows other recent immuno-oncology tie-ups by AstraZeneca
with Sosei subsidiary Heptares and Mirati.
(Reporting by Ben Hirschler; Editing by Susan Fenton)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
